As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn't yet been approved ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation.

Healthcare stocks, especially biopharmaceuticals, are forecasted to outperform the market due to four key investment themes.

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.

GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly ...

The Study is designed mainly to determine whether Lexaria’s proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs. “Achieving the first patient, first dose ...

Hims & Hers stock took a hit today after the FDA ruled no shortage of tirzepatide, impacting their compounded GLP-1 drug offerings. Despite the setback, Hims & Hers' CEO will likely remain defiant ...

Mer­ck is fi­nal­ly mak­ing a move in obe­si­ty by li­cens­ing an oral GLP-1 can­di­date, though it’s hap­pen­ing years af­ter some of its big phar­ma peers … ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...

Nestlé’s efforts to attract users of GLP-1 drugs in the US now include the launch of protein shots. The company is rolling out Boost Pre-meal, a liquid shot the Swiss giant said will “support ...